Catalyst Cash vs Common Stock Total Equity Analysis

CPRX Stock

USD 21.97 0.14 0.63%

Catalyst Pharmaceuticals financial indicator trend analysis is way more than just evaluating Catalyst Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Catalyst Pharmaceuticals is a good investment. Please check the relationship between Catalyst Pharmaceuticals Cash and its Common Stock Total Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.

Cash vs Common Stock Total Equity

Cash vs Common Stock Total Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Catalyst Pharmaceuticals Cash account and Common Stock Total Equity. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Catalyst Pharmaceuticals' Cash and Common Stock Total Equity is 0.59. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Common Stock Total Equity in the same time period over historical financial statements of Catalyst Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Catalyst Pharmaceuticals' Cash and Common Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of Catalyst Pharmaceuticals are associated (or correlated) with its Common Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Total Equity has no effect on the direction of Cash i.e., Catalyst Pharmaceuticals' Cash and Common Stock Total Equity go up and down completely randomly.

Correlation Coefficient

0.59

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Cash

Cash refers to the most liquid asset of Catalyst Pharmaceuticals, which is listed under current asset account on Catalyst Pharmaceuticals balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Catalyst Pharmaceuticals customers. The amounts must be unrestricted with restricted cash listed in a different Catalyst Pharmaceuticals account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Most indicators from Catalyst Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Catalyst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.At this time, Catalyst Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 19.7 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.11 in 2024.

	2023	2024 (projected)
Reconciled Depreciation	24.4M	25.6M
Net Interest Income	1.8M	1.0M

Reconciled Depreciation Net Interest Income

Catalyst Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Non Current Assets Total	Common Stock Total Equity	Property Plant And Equipment Gross	Common Stock	Property Plant Equipment	Non Currrent Assets Other	Other Current Assets	Net Receivables	Other Liab	Non Current Liabilities Total	Net Tangible Assets
Total Assets		1.0	-0.8	0.82	0.31	0.79	0.49	0.8	0.98	0.91	0.98	0.99	0.91	0.79	0.9	0.89	0.51	0.93	0.48	0.47	-0.8	0.93	0.83	0.86	0.72	0.99
Total Stockholder Equity	1.0		-0.79	0.81	0.32	0.79	0.5	0.81	0.97	0.91	0.98	0.98	0.91	0.79	0.9	0.89	0.53	0.93	0.5	0.48	-0.8	0.93	0.83	0.86	0.71	0.99
Net Debt	-0.8	-0.79		-1.0	-0.65	-0.99	-0.63	-0.74	-0.79	-0.97	-0.73	-0.75	-0.81	-0.52	-0.47	-0.44	-0.6	-0.77	-0.61	-0.54	0.33	-0.63	-0.35	-0.82	-0.88	-0.84
Cash	0.82	0.81	-1.0		0.64	0.99	0.62	0.75	0.81	0.97	0.75	0.77	0.83	0.54	0.5	0.47	0.59	0.79	0.6	0.54	-0.36	0.65	0.38	0.83	0.88	0.86
Other Assets	0.31	0.32	-0.65	0.64		0.65	0.46	0.39	0.23	0.55	0.25	0.21	0.31	0.12	-0.01	-0.03	0.4	0.26	0.43	0.48	0.13	0.3	-0.18	0.53	0.47	0.42
Cash And Short Term Investments	0.79	0.79	-0.99	0.99	0.65		0.69	0.79	0.77	0.97	0.72	0.73	0.81	0.46	0.45	0.42	0.66	0.77	0.67	0.57	-0.33	0.61	0.35	0.79	0.86	0.84
Common Stock Shares Outstanding	0.49	0.5	-0.63	0.62	0.46	0.69		0.86	0.44	0.66	0.39	0.44	0.46	-0.08	0.33	0.21	0.98	0.43	0.98	0.39	-0.31	0.45	0.27	0.56	0.38	0.56
Other Stockholder Equity	0.8	0.81	-0.74	0.75	0.39	0.79	0.86		0.74	0.84	0.71	0.76	0.71	0.27	0.68	0.59	0.87	0.71	0.87	0.46	-0.62	0.76	0.63	0.76	0.5	0.84
Total Liab	0.98	0.97	-0.79	0.81	0.23	0.77	0.44	0.74		0.9	0.97	0.99	0.9	0.81	0.88	0.88	0.45	0.92	0.42	0.39	-0.78	0.89	0.82	0.85	0.77	0.96
Total Current Assets	0.91	0.91	-0.97	0.97	0.55	0.97	0.66	0.84	0.9		0.86	0.87	0.89	0.61	0.66	0.63	0.64	0.87	0.64	0.56	-0.54	0.77	0.56	0.87	0.85	0.95
Other Current Liab	0.98	0.98	-0.73	0.75	0.25	0.72	0.39	0.71	0.97	0.86		0.98	0.89	0.85	0.9	0.92	0.41	0.92	0.37	0.43	-0.81	0.9	0.85	0.8	0.72	0.96
Total Current Liabilities	0.99	0.98	-0.75	0.77	0.21	0.73	0.44	0.76	0.99	0.87	0.98		0.89	0.81	0.92	0.91	0.46	0.92	0.43	0.39	-0.82	0.92	0.86	0.86	0.7	0.96
Property Plant And Equipment Net	0.91	0.91	-0.81	0.83	0.31	0.81	0.46	0.71	0.9	0.89	0.89	0.89		0.73	0.73	0.74	0.45	0.99	0.43	0.74	-0.64	0.75	0.67	0.81	0.7	0.91
Retained Earnings	0.79	0.79	-0.52	0.54	0.12	0.46	-0.08	0.27	0.81	0.61	0.85	0.81	0.73		0.75	0.84	-0.05	0.77	-0.1	0.3	-0.65	0.72	0.7	0.61	0.62	0.74
Accounts Payable	0.9	0.9	-0.47	0.5	-0.01	0.45	0.33	0.68	0.88	0.66	0.9	0.92	0.73	0.75		0.98	0.38	0.79	0.33	0.25	-0.94	0.94	0.97	0.74	0.41	0.85
Non Current Assets Total	0.89	0.89	-0.44	0.47	-0.03	0.42	0.21	0.59	0.88	0.63	0.92	0.91	0.74	0.84	0.98		0.26	0.81	0.21	0.26	-0.92	0.91	0.97	0.68	0.43	0.84
Common Stock Total Equity	0.51	0.53	-0.6	0.59	0.4	0.66	0.98	0.87	0.45	0.64	0.41	0.46	0.45	-0.05	0.38	0.26		0.43	0.99	0.36	-0.33	0.48	0.33	0.54	0.34	0.58
Property Plant And Equipment Gross	0.93	0.93	-0.77	0.79	0.26	0.77	0.43	0.71	0.92	0.87	0.92	0.92	0.99	0.77	0.79	0.81	0.43		0.41	0.69	-0.71	0.79	0.75	0.82	0.67	0.93
Common Stock	0.48	0.5	-0.61	0.6	0.43	0.67	0.98	0.87	0.42	0.64	0.37	0.43	0.43	-0.1	0.33	0.21	0.99	0.41		0.37	-0.28	0.44	0.28	0.52	0.33	0.55
Property Plant Equipment	0.47	0.48	-0.54	0.54	0.48	0.57	0.39	0.46	0.39	0.56	0.43	0.39	0.74	0.3	0.25	0.26	0.36	0.69	0.37		-0.21	0.33	0.2	0.52	0.28	0.53
Non Currrent Assets Other	-0.8	-0.8	0.33	-0.36	0.13	-0.33	-0.31	-0.62	-0.78	-0.54	-0.81	-0.82	-0.64	-0.65	-0.94	-0.92	-0.33	-0.71	-0.28	-0.21		-0.84	-0.95	-0.6	-0.31	-0.74
Other Current Assets	0.93	0.93	-0.63	0.65	0.3	0.61	0.45	0.76	0.89	0.77	0.9	0.92	0.75	0.72	0.94	0.91	0.48	0.79	0.44	0.33	-0.84		0.86	0.87	0.49	0.91
Net Receivables	0.83	0.83	-0.35	0.38	-0.18	0.35	0.27	0.63	0.82	0.56	0.85	0.86	0.67	0.7	0.97	0.97	0.33	0.75	0.28	0.2	-0.95	0.86		0.6	0.31	0.77
Other Liab	0.86	0.86	-0.82	0.83	0.53	0.79	0.56	0.76	0.85	0.87	0.8	0.86	0.81	0.61	0.74	0.68	0.54	0.82	0.52	0.52	-0.6	0.87	0.6		0.63	0.89
Non Current Liabilities Total	0.72	0.71	-0.88	0.88	0.47	0.86	0.38	0.5	0.77	0.85	0.72	0.7	0.7	0.62	0.41	0.43	0.34	0.67	0.33	0.28	-0.31	0.49	0.31	0.63		0.73
Net Tangible Assets	0.99	0.99	-0.84	0.86	0.42	0.84	0.56	0.84	0.96	0.95	0.96	0.96	0.91	0.74	0.85	0.84	0.58	0.93	0.55	0.53	-0.74	0.91	0.77	0.89	0.73

Click cells to compare fundamentals

Catalyst Pharmaceuticals Account Relationship Matchups

Catalyst Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	112.4M	192.4M	237.8M	375.6M	470.1M	493.6M
Total Stockholder Equity	87.6M	169.6M	206.8M	300.4M	387.9M	407.3M
Net Debt	(88.9M)	(130.2M)	(167.6M)	(294.5M)	(134.1M)	(127.4M)
Cash	89.5M	130.2M	171.4M	298.4M	137.6M	144.5M
Cash And Short Term Investments	94.5M	140.3M	191.3M	298.4M	137.6M	144.5M
Common Stock Shares Outstanding	106.0M	106.2M	107.8M	111.4M	113.8M	57.0M
Liabilities And Stockholders Equity	112.4M	192.4M	237.8M	375.6M	470.1M	493.6M
Other Stockholder Equity	216.2M	223.2M	233.2M	250.4M	266.5M	279.8M
Total Liab	24.7M	22.8M	31.0M	75.2M	82.2M	86.3M
Total Current Assets	111.4M	159.2M	210.1M	320.8M	219.3M	230.3M
Other Current Liab	172.3K	18.5M	23.9M	44.6M	60.2M	63.2M
Total Current Liabilities	24.1M	22.8M	27.1M	57.6M	76.1M	79.9M
Property Plant And Equipment Net	1.0M	129.8K	4.0M	3.6M	3.7M	3.9M
Retained Earnings	(128.7M)	(53.7M)	(26.3M)	49.9M	121.3M	127.3M
Accounts Payable	4.1M	4.3M	2.8M	4.0M	14.8M	15.5M
Non Current Assets Total	1.0M	33.1M	27.7M	54.8M	250.8M	263.3M
Common Stock Total Equity	103.4K	103.8K	103K	105K	120.8K	66.6K
Property Plant And Equipment Gross	1.0M	129.8K	4.0M	3.6M	4.4M	4.6M
Accumulated Other Comprehensive Income	9.5K	31.3K	(148K)	24K	14K	14.7K
Common Stock	103.4K	103.8K	103K	105K	107K	69.1K
Property Plant Equipment	210.5K	129.8K	4.0M	847K	974.1K	1.0M
Other Current Assets	4.4M	8.3M	4.4M	5.2M	12.5M	13.2M
Non Current Liabilities Total	647.5K	4.3M	3.9M	17.6M	6.2M	6.5M
Net Tangible Assets	87.6M	169.6M	206.8M	268.0M	308.1M	323.5M
Retained Earnings Total Equity	(160.6M)	(128.7M)	(26.3M)	49.9M	57.3M	60.2M
Capital Surpluse	211.3M	216.2M	233.2M	250.4M	288.0M	169.1M
Inventory	2.0M	4.7M	7.9M	6.8M	15.6M	16.4M
Non Current Liabilities Other	154.8K	647.5K	3.9M	17.6M	485K	460.8K
Net Invested Capital	87.6M	169.6M	206.8M	300.4M	387.9M	201.8M
Net Working Capital	87.3M	136.5M	183.0M	263.2M	143.3M	147.7M
Capital Stock	103.4K	103.8K	103K	105K	107K	114.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Catalyst Cash vs Common Stock Total Equity Analysis

Cash vs Common Stock Total Equity

Cash vs Common Stock Total Equity Correlation Analysis

Correlation Coefficient

Cash

Common Stock Total Equity

Catalyst Pharmaceuticals fundamental ratios Correlations

Catalyst Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Catalyst Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Catalyst Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Liabilities	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Cash
Total Current Liabilities	+ 0.99	Total Liab

Cash	- 1.0	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Total Current Assets	- 0.97	Net Debt
Net Receivables	- 0.95	Non Currrent Assets Other
Non Currrent Assets Other	- 0.94	Accounts Payable
Non Currrent Assets Other	- 0.92	Non Current Assets Total